Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder.

Laffont, Celine M; Ngaimisi, Eliford; Gopalakrishnan, Mathangi; Ivaturi, Vijay; Young, Malcolm; Greenwald, Mark K; Heidbreder, Christian

Laffont, Celine M; Ngaimisi, Eliford; Gopalakrishnan, Mathangi; Ivaturi, Vijay; Young, Malcolm; Greenwald, Mark K; Heidbreder, Christian.

Afiliação

Laffont CM; Indivior Inc., North Chesterfield, VA, United States.
Ngaimisi E; Center for Translational Medicine, University of Maryland, Baltimore, MD, United States.
Gopalakrishnan M; Center for Translational Medicine, University of Maryland, Baltimore, MD, United States.
Ivaturi V; Center for Translational Medicine, University of Maryland, Baltimore, MD, United States.
Young M; Indivior Inc., North Chesterfield, VA, United States.
Greenwald MK; Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, United States.
Heidbreder C; Indivior Inc., North Chesterfield, VA, United States.

Front Pharmacol ; 13: 1052113, 2022.

Article em En | MEDLINE | ID: mdl-36467036

Palavras-chave

(extended-release) buprenorphine; craving; exposure-response; opioid blockade; opioid use disorder; optimized treatment outcome; withdrawal

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Aspecto: Equity_inequality Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google